Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for TNF Inhibitors for the Treatment of Plaque Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for TNF Inhibitors for the Treatment of Plaque Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for TNF Inhibitors for the Treatment of Plaque Psoriasis sales, projected growth trends, production technology, application and end-user industry.
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company
Chia Tai Tianqing Pharmaceutical
Innovent Biologics
Sino Cell Technologies
Samsung Bioepis
Hangzhou Bozhirui Biopharmaceuticals
Hisun Pharmaceuticals
Bio-Thera Solutions
YL Biologics
UCB
Teva
Sandoz
Pfizer
Janssen Biotech
Coherus BioSciences
Celltrion
Boehringer Ingelheim Pharmaceuticals
Biocon Biologics
Amgen
AbbVie
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type
Adalimumab
Certolizumab pegol
Etanercept
Infliximab
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the TNF Inhibitors for the Treatment of Plaque Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for TNF Inhibitors for the Treatment of Plaque Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for TNF Inhibitors for the Treatment of Plaque Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for TNF Inhibitors for the Treatment of Plaque Psoriasis sales, projected growth trends, production technology, application and end-user industry.
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company
Chia Tai Tianqing Pharmaceutical
Innovent Biologics
Sino Cell Technologies
Samsung Bioepis
Hangzhou Bozhirui Biopharmaceuticals
Hisun Pharmaceuticals
Bio-Thera Solutions
YL Biologics
UCB
Teva
Sandoz
Pfizer
Janssen Biotech
Coherus BioSciences
Celltrion
Boehringer Ingelheim Pharmaceuticals
Biocon Biologics
Amgen
AbbVie
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type
Adalimumab
Certolizumab pegol
Etanercept
Infliximab
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the TNF Inhibitors for the Treatment of Plaque Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
197 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size, 2020 VS 2024 VS 2031
- 1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Estimates and Forecasts (2020-2031)
- 1.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Dynamics
- 2.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
- 2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
- 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
- 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
- 3 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Manufacturers
- 3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers (2020-2025)
- 3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers (2020-2025)
- 3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers, Product Type & Application
- 3.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 TNF Inhibitors for the Treatment of Plaque Psoriasis Players Market Share by Revenue in 2024
- 3.8.3 2024 TNF Inhibitors for the Treatment of Plaque Psoriasis Tier 1, Tier 2, and Tier 3
- 4 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
- 4.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Type Introduction
- 4.1.1 Adalimumab
- 4.1.2 Certolizumab pegol
- 4.1.3 Etanercept
- 4.1.4 Infliximab
- 4.1.5 Other
- 4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type
- 4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2020-2031)
- 4.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2020-2031)
- 4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type
- 4.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2020-2031)
- 4.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2020-2031)
- 5 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
- 5.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Application Introduction
- 5.1.1 Hospital and Clinic
- 5.1.2 Retail Pharmacies
- 5.1.3 Other
- 5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application
- 5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2020-2031)
- 5.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2020-2031)
- 5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application
- 5.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2020-2031)
- 5.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2020-2031)
- 6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region
- 6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2020-2031)
- 6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2020-2025)
- 6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region
- 7.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region
- 7.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2020-2025)
- 7.1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2026-2031)
- 7.1.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2020-2031)
- 7.2.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2020-2031)
- 7.3.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2020-2031)
- 7.4.2 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Chia Tai Tianqing Pharmaceutical
- 8.1.1 Chia Tai Tianqing Pharmaceutical Comapny Information
- 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 8.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 8.2 Innovent Biologics
- 8.2.1 Innovent Biologics Comapny Information
- 8.2.2 Innovent Biologics Business Overview
- 8.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.2.5 Innovent Biologics Recent Developments
- 8.3 Sino Cell Technologies
- 8.3.1 Sino Cell Technologies Comapny Information
- 8.3.2 Sino Cell Technologies Business Overview
- 8.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.3.5 Sino Cell Technologies Recent Developments
- 8.4 Samsung Bioepis
- 8.4.1 Samsung Bioepis Comapny Information
- 8.4.2 Samsung Bioepis Business Overview
- 8.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.4.5 Samsung Bioepis Recent Developments
- 8.5 Hangzhou Bozhirui Biopharmaceuticals
- 8.5.1 Hangzhou Bozhirui Biopharmaceuticals Comapny Information
- 8.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
- 8.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
- 8.6 Hisun Pharmaceuticals
- 8.6.1 Hisun Pharmaceuticals Comapny Information
- 8.6.2 Hisun Pharmaceuticals Business Overview
- 8.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.6.5 Hisun Pharmaceuticals Recent Developments
- 8.7 Bio-Thera Solutions
- 8.7.1 Bio-Thera Solutions Comapny Information
- 8.7.2 Bio-Thera Solutions Business Overview
- 8.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.7.5 Bio-Thera Solutions Recent Developments
- 8.8 YL Biologics
- 8.8.1 YL Biologics Comapny Information
- 8.8.2 YL Biologics Business Overview
- 8.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.8.5 YL Biologics Recent Developments
- 8.9 UCB
- 8.9.1 UCB Comapny Information
- 8.9.2 UCB Business Overview
- 8.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.9.5 UCB Recent Developments
- 8.10 Teva
- 8.10.1 Teva Comapny Information
- 8.10.2 Teva Business Overview
- 8.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.10.5 Teva Recent Developments
- 8.11 Sandoz
- 8.11.1 Sandoz Comapny Information
- 8.11.2 Sandoz Business Overview
- 8.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.11.5 Sandoz Recent Developments
- 8.12 Pfizer
- 8.12.1 Pfizer Comapny Information
- 8.12.2 Pfizer Business Overview
- 8.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.12.5 Pfizer Recent Developments
- 8.13 Janssen Biotech
- 8.13.1 Janssen Biotech Comapny Information
- 8.13.2 Janssen Biotech Business Overview
- 8.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.13.5 Janssen Biotech Recent Developments
- 8.14 Coherus BioSciences
- 8.14.1 Coherus BioSciences Comapny Information
- 8.14.2 Coherus BioSciences Business Overview
- 8.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.14.5 Coherus BioSciences Recent Developments
- 8.15 Celltrion
- 8.15.1 Celltrion Comapny Information
- 8.15.2 Celltrion Business Overview
- 8.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.15.5 Celltrion Recent Developments
- 8.16 Boehringer Ingelheim Pharmaceuticals
- 8.16.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
- 8.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
- 8.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
- 8.17 Biocon Biologics
- 8.17.1 Biocon Biologics Comapny Information
- 8.17.2 Biocon Biologics Business Overview
- 8.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.17.5 Biocon Biologics Recent Developments
- 8.18 Amgen
- 8.18.1 Amgen Comapny Information
- 8.18.2 Amgen Business Overview
- 8.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.18.5 Amgen Recent Developments
- 8.19 AbbVie
- 8.19.1 AbbVie Comapny Information
- 8.19.2 AbbVie Business Overview
- 8.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
- 8.19.5 AbbVie Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
- 9.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process
- 9.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
- 9.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
